Single-cell profiling guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphoma.
Oliver Holger KrämerGünter SchneiderPublished in: Clinical and translational medicine (2022)
In this commentary on Wang, Wu, Xia, and colleagues, Clinical Translational Medicine, 2022, we sum up and discuss recent evidence on the regulation and relevance of the transcription factor c-FOS in diffuse large B cell lymphoma cells that are treated with epigenetic erasers of the histone deacetylase inhibitor family.
Keyphrases
- diffuse large b cell lymphoma
- histone deacetylase
- combination therapy
- single cell
- transcription factor
- epstein barr virus
- induced apoptosis
- rna seq
- cell cycle arrest
- dna methylation
- gene expression
- high throughput
- endoplasmic reticulum stress
- dna binding
- oxidative stress
- signaling pathway
- cell proliferation
- newly diagnosed
- pi k akt